Compare Eli Lilly And Co (LLY) vs Zillow Group Inc Class C (Z) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Zillow Group (Z) trades at $33.03, down 2.58% today, amid ongoing class action lawsuits alleging securities fraud between February 2025 and May 2026. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, revenue grew to $2.58B in 2025 with a net income of $23M, yet high P/E of 135.72 reflects premium valuation. Analyst consensus is divided with 46% Buy, 50% Hold, and a $57.67 price target implying significant upside from current levels.

The outlook is clouded by legal risks and volatile cash flows, but improving profitability and analyst targets suggest long-term potential if the company navigates litigation successfully. Key risks include lawsuit outcomes and competitive pressures in real estate tech, while institutional sentiment remains cautiously optimistic given the growth trajectory.